Determination of Plasma Concentration Reference Ranges for Risperidone and Paliperidone
| Autor: | Julia Korell, Bruce Green, An Vermeulen, Bart Remmerie |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
education.field_of_study Risperidone business.industry Population Therapeutic effect medicine.disease 030226 pharmacology & pharmacy 030227 psychiatry 03 medical and health sciences 0302 clinical medicine Therapeutic index Pharmacokinetics Schizophrenia Modeling and Simulation medicine Pharmacology (medical) Paliperidone Adverse effect Psychiatry education Intensive care medicine business medicine.drug |
| Zdroj: | CPT: Pharmacometrics & Systems Pharmacology. 6:589-595 |
| ISSN: | 2163-8306 |
| DOI: | 10.1002/psp4.12217 |
| Popis: | Schizophrenia is a common disease managed by a range of interventions, with the primary treatment being antipsychotic medications (APS). Inadequate response, lack of adherence, and/or adverse events often prevent optimal therapeutic effects or therapeutic efficiency. Monitoring APS plasma concentrations can be used together with a full clinical evaluation to help improve patient care or offer better treatment options for the patient. To enable interpretation of individual risperidone and paliperidone plasma concentrations, we developed "reference ranges," which consider the expected variability in plasma concentrations between subjects across the population, rather than representing a "therapeutic range" that relates to efficacy and/or safety outcomes. The reference ranges were derived from population pharmacokinetic models, which varied based upon administration route, dose, and time after dose. Good agreement between the proposed reference ranges and external data was obtained through graphical and numerical evaluations, indicating they could be reliably used in clinical practice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|